CEN Case Reports

, Volume 7, Issue 1, pp 137–142 | Cite as

Combined membranous nephropathy and tubulointerstitial nephritis as a rare renal manifestation of IgG4-related disease: a case-based literature review

  • Wei Zhang
  • Jeffrey H. Glaze
  • David Wynne
Case Report


IgG4-related disease (IgG4-RD) is a newly recognized immune-mediated multisystemic disease characterized by a fibro-inflammatory condition with tissue infiltration of IgG4-positive plasma cells and often associated with elevated serum IgG4 levels. Typical renal involvement of IgG4-RD presents as tubulointerstitial nephritis (TIN), membranous or membranoproliferative nephropathy. We are presenting a case with combined IgG4 membranous nephropathy and TIN, as well as a literature review on pathophysiology, diagnosis and treatment of IgG4-RD. A 62-year-old man presented with weight loss and fatigue. Labs showed significant proteinuria and hematuria with elevated serum creatinine (2.5 mg/dL). CT/PET scan found scattered lymphadenopathy without increased FDG uptake. Kidney biopsy showed glomerular lesions as well as severe interstitial fibrosis and tubular atrophy. Immunohistochemistry study was negative for anti-phospholipase A2 receptor antibodies and showed interstitial lymphocytic infiltration with IgG4 positive plasma cells. Patient also had elevated serum IgG4 level and IgG4 to total IgG ratio. Prednisone treatment was initiated soon after the diagnosis was made, patient responded well with proteinuria and hematuria both resolved. IgG4-related disease (IgG4-RD) is a newly increasingly recognized immune-mediated multisystemic disease; IgG4-related membranous nephropathy should be included in the differential diagnosis for patients with proteinuria.


IgG4-related disease Membranous nephropathy Secondary membranous nephropathy Tubulointerstitial nephritis 


Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interests to disclose. Consent, for the publication of this case report and any additional related information, was taken from the patient involved in the study. This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Geyer JT, Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol. 2011;23(1):95–101.CrossRefPubMedGoogle Scholar
  3. 3.
    Kamisawa T, Takuma K, Egawa N, et al. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol. 2010;7(7):401–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178(2):661–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Nirula A, Glaser SM, Kalled SL, et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23(1):119–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.CrossRefPubMedGoogle Scholar
  8. 8.
    Dhall D, Suriawinata AA, Tang LH, et al. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol. 2010;41(5):643–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic’s HISORt criteria. J Gastroenterol. 2007;42(Suppl 18):39–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Alexander MP, Larsen CP, Gibson IW, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int. 2013;83(3):455–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Kurien AA, Raychaudhury A, Walker PD. Membranous nephropathy as a rare renal manifestation of IgG4-related disease. Indian J Nephrol. 2015;25(3):164–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jindal N, Yadav D, Passero C, et al. Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease. Clin Nephrol. 2012;77(4):321–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheumat. 2012;64(10):3061–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Okazaki K, Umehara H. Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan. Int J Rheumatol. 2012;2012:357071.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fervenza FC, Downer G, Beck LH Jr, et al. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis. 2011;58(2):320–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68(1):302–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23(1):67–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45(5):471–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine. 2012;91(1):57–66.CrossRefPubMedGoogle Scholar
  21. 21.
    Stone JH. IgG4-related disease: pathophysiologic insights drive emerging treatment approaches. Clin Exp Rheumatol. 2016;34(4 Suppl 98):66–8.PubMedGoogle Scholar
  22. 22.
    Perugino CA, Stone JH. Treatment of IgG4-related disease: current and future approaches. Z Rheumatol. 2016;75(7):681–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Carruthers MN, Stone JH, Deshpande V, et al. Development of an IgG4-RD responder index. Int J Rheumatol. 2012;2012:259408.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheumat Dis. 2015;74(1):190–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Lanzillotta M, Della-Torre E, Stone JH. Roles of plasmablasts and B cells in IgG4-related disease: implications for therapy and early treatment outcomes. Curr Top Microbiol Immunol. 2017;401:85–92.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Internal Medicine Residency ProgramBrookwood Baptist HealthBirminghamUSA
  2. 2.Nephrology Associates, P.C.BirminghamUSA
  3. 3.Summit Internal MedicineBirminghamUSA

Personalised recommendations